Epidemiology of ventilator-associated pneumonia in ICU COVID-19 patients: an alarming high rate of multidrug-resistant bacteria

Nardi Tetaj1,2*, Alessandro Capone3, Giulia Valeria Stazi1,2, Maria Cristina Marini1,2, Gabriele Garotto1,2, Donatella Busso1,2, Silvana Scarcia1,2, Ilaria Caravella1,2, Manuela Macchione1,2, Giada De Angelis1,2, Rachele Di Lorenzo1,2, Alessandro Carucci1,2, Maria Vittoria Antonica1,2, Ilaria Gaviano1,2, Carlo Inversi1,2, Elisabetta Agostini1,2, Flaminia Canichella1,2, Giorgia Taloni1,2, Francesca Evangelista1,2, Ilaria Onnis1,2, Giulia Mogavero1,2, Maria Elena Lamanna1,2, Dorotea Rubino1,2, Mattia Di Frischia1,2, Candido Porcelli1,2, Elena Cesì1,2, Andrea Antinori3, Fabrizio Palmieri3, Gianpiero D’Offizi3, Fabrizio Taglietti3, Carla Nisi3, Maria Adriana Cataldo3, Stefania Ianniello3, Paolo Campioni3, Francesco Vaia4, Emanuele Nicastrì3, Enrico Girardi5, Luisa Marchioni1,2 and ICU COVID-19 Study Group

Abstract

Background: COVID-19 is a novel cause of acute respiratory distress syndrome (ARDS) that leads patients to intensive care unit (ICU) admission requiring invasive ventilation, who consequently are at risk of developing of ventilator-associated pneumonia (VAP). The aim of this study was to assess the incidence, antimicrobial resistance, risk factors, and outcome of VAP in COVID-19 patients in invasive mechanical ventilation (MV).

Methods: Observational prospective study including adult ICU admissions between January 1, 2021, and June 31, 2021, with confirmed COVID-19 diagnosis were recorded daily, including demographics, medical history, ICU clinical data, etiology of VAPs, and the outcome. The diagnosis of VAP was based on multi-criteria decision analysis which included a combination of radiological, clinical, and microbiological criteria in ICU patients in MV for at least 48 h.

Results: Two hundred eighty-four COVID-19 patients in MV were admitted in ICU. Ninety-four patients (33%) had VAP during the ICU stay, of which 85 had a single episode of VAP and 9 multiple episodes. The median time of onset of VAP from intubation were 8 days (IQR, 5–13). The overall incidence of VAP was of 13.48 episodes per 1000 days in MV. The main etiological agent was *Pseudomonas aeruginosa* (39.8% of all VAPs) followed by Klebsiella spp. (16.5%); of them, 41.4% and 17.6% were carbapenem resistant, respectively. Patients during the mechanical ventilation in orotracheal intubation (OTI) had a higher incidence than those in tracheostomy, 16.46 and 9.8 episodes per 1000-MV day, respectively. An increased risk of VAP was reported in patients receiving blood transfusion (OR 2.13, 95% CI 1.26–3.59, \( p = 0.005 \)) or therapy with Tocilizumab/Sarilumab (OR 2.08, 95% CI 1.12–3.84, \( p = 0.02 \)). The pronation and PaO\(_2\)/FiO\(_2\)
Background
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a coronavirus discovered in December 2019, named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and it is responsible for the current global pandemic that started in March 2020 [1]. COVID-19 can cause lung complications such as pneumonia and in the most severe cases ARDS. In COVID-19 patients with persistent hypoxemia who are unresponsive to non-invasive ventilation (NIV), orotracheal intubation (OTI) is necessary and ICU admission is required in patients with persistent hypoxemia [2]. In the event of expected long-term mechanical ventilation or failed weaning, tracheostomy is indicated [3].

Ventilator-associated pneumonia (VAP), one of the most common health care-related infectious complications of invasive mechanical ventilation, may increase the intensity of medical care and also complicate the outcome of ICU patients.

Koulenti et al. in 2016 reported in the EU-VAP/CAP study, a multicenter retrospective observational study referring to a period from 1999 to 2006, enrolling patients from 27 ICUs in nine European countries, the incidence of VAP with 18.3 events per 1000 ventilator days [4]. In the past decade, there has been a reduction in the incidence of VAPs in European ICUs, probably due to better implementation of preventive strategies [5]. Indeed, more recently, in 2019, the European Centre for Disease Prevention and Control (ECDC) reported an incidence of VAP of 9.5 episodes per 1000 intubation days, based on data from 1192 hospitals and 1480 ICUs, where 14 countries participated [6].

Furthermore, the Italian PROSAFE project report of 2018, performed by GiViTi (Italian Group for the Evaluation of Interventions in Intensive Care) which includes data collected from 122 ICUs in Italy, found that the incidence of VAP in patients mechanically ventilated for at least 8 days was 9.8 events per 1000 ventilator days (CI 95%, 9.2–10.4) [7].

Forel et. al. in 2012 showed that VAP occurred in almost one third of patients with acute respiratory distress syndrome (ARDS) in intensive care unit (ICU) and were associated with an increase ICU mortality which did not remain significant after adjustment [8].

The aforementioned studies refer to the pre-COVID-19 era. Data in literature show that patients with COVID-19 may have a higher risk of developing VAP than patients without COVID-19, as reported in two recent multicenter Italian studies performed in 2021 on COVID-19 patients by Grasselli et al. and Giacobbe et al., with an incidence of 18 and 26 events per 1000 ventilator days [9, 10], respectively. A further study conducted in France by Blonz et al. reports an incidence of VAPs of 39.0 episodes per 1000 ventilator days [11]. Few of these studies have investigated risk factors. Still, incidence, risk factors, and mortality rates associated with VAP in ARDS COVID-19 patients are unclear and a matter of debate [11, 12].

The primary objective of this prospective observational study was to assess the prevalence and incidence rates of VAP in COVID-19 patients in ICU. The secondary objective was to assess the frequency of microbial isolates, pattern of antimicrobial resistance, risk factors associated with VAP, and ICU mortality in VAP patients.

Material and methods
Study design and definitions
A prospective cohort study was conducted at the “Lazzaro Spallanzani” National Institute for Infectious Disease (INMI) in Rome, Italy, which is a third level COVID-19 center with 200-bed hospital for infectious disease and 55-bed in ICU.

In the present study, adult COVID-19 patients admitted to our ICU from January 1, 2021, to June 31, 2021, and underwent invasive mechanical ventilation for at least 7 days were included.

Patients transferred to another hospital and those still hospitalized at ICU at the end of the study were excluded. COVID-19 was diagnosed by nasal pharyngeal swab for reverse transcriptase polymerase chain reaction (rt-PCR) assay. The diagnosis of VAP was based on multicriteria decision analysis adapted from the ECDC recommendations [5] and Clinical Practice Guidelines by the
Infectious Diseases Society of America and the American Thoracic Society [13], which included a combination of radiological, clinical, and microbiological criteria in ICU patients in invasive mechanical ventilation (MV) for at least 48 h. VAPs were diagnosed by Clinical Research Coordinators based on their experience in clinical practice and publications. They also contributed to the supervision and the review of the study.

The clinical criteria included at least one of the following signs: fever > 38 °C with no other cause, leukocytes < 4000/mm³ or > 12,000/mm³, and at least one of the following: new onset of purulent sputum or change in character of sputum (color, odor, quantity, consistency), worsening gas exchange – PaO₂/FiO₂ ratio which is the ratio of arterial partial pressure (PaO₂) to fractional inspired oxygen (FiO₂). The radiological criteria included new or worsening infiltrates on lung CT. Regarding microbiological criteria the American guidelines [13] recommend non-invasive and semi-quantitative sampling, and European guidelines (ECDC) [5] recommend invasive and quantitative sampling. In our study, serial blind bronchoalveolar lavages were performed every 72 h in every intubated patient with the semi-quantitative sampling. In case of rare species, which corresponds from 10³ to 10⁴ CFU/ml in our microbiology laboratory in semi-quantitative sampling, the etiologic agent has not been considered and the VAP was not diagnosed. Positive quantitative culture from minimally contaminated lower respiratory tract (LRT) specimen was considered a threshold of 10⁴ colony-forming units (CFU)/mL for bronchoscopy bronchoalveolar lavage; or a threshold of 10⁵ CFU/ml from endotracheal aspirate.

Patients on MV up to weaning were given continuous intravenous sedatives to help attenuate the anxiety, pain, and agitation associated with mechanical ventilation. Nutritional support in ICU was performed according to the European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines [14].

Percutaneous tracheostomy was performed in patients with prolonged mechanical ventilation and weaning failure from mechanical ventilator [15].

Data collection
For each enrolled patient, the following data were prospectively collected: age, gender, and body mass index (BMI); sequential organ failure assessment score (SOFA score), acute physiology and chronic health evaluation II score (APACHE II score), and PaO₂/FiO₂ at ICU admission; pre-ICU hospitalization as days of hospitalization in the ward until admission to intensive care, ICU length of stay, and etiology of VAPs. Also, corticosteroid therapy, antiviral therapy (tocilizumab or sarilumab), previous antibiotic therapy (30 days before orotracheal intubation), blood transfusions during ICU stay, hemodialysis, barotrauma (pneumothorax or pneumome- diastinum), and pronation at least 1 cycle of 12 h were collected during the ICU hospitalization.

The comorbidities included arterial hypertension, cardiovascular diseases, diabetes, obesity (defined as BMI > 30 kg/m²), chronic renal disease in stages 3–5 of CKD (chronic kidney disease), chronic liver disease (moderate to severe liver disease), chronic lung diseases (which included chronic obstructive pulmonary disease—COPD, bronchial asthma, emphysema, or other pulmonary diseases), previous neoplasm (during the last 5 years, which includes solid neoplasia or hematological malignancy), chronic neurological disorders, autoimmune diseases, and other chronic diseases (which includes all other less common diseases). We also recorded previous hospitalization in last 6 months, previous surgery in the last month. During the ICU hospitalization of included patients, Clinical Research Coordinators as trained healthcare personnel assessed patients for the occurrence of VAP. Finally, a 30-day and 60-day-mortality were recorded, along with the total length of ICU hospitalization and of IVM, performing of tracheostomy.

Statistical analysis
The prevalence rate of VAP was calculated by dividing the number of patients who acquired VAP by the total number of included patients. The incidence rate of VAP was calculated as number of episodes/1000 days of invasive mechanical ventilation in both orotracheal intubation and tracheostomy procedures.

To assess potential risk factors associated with VAP, patients with VAP were compared with patients who did not acquire VAP during ICU stay.

Quantitative variables are expressed as medians (interquartile range, IQR), while categorical variables were expressed as counts (N) and percentages (%). The statistical comparison was performed by means of the Mann–Whitney test for continuous variables and chi-square test (or Fisher or chi-square test for trend where necessary) for categorical variables.

Potential risk factors for VAP were analysed by univariate analysis. Two-tailed p values < 0.05 were considered statistically significant. Variables from the univariate analysis were considered for inclusion in multivariate logistic regression analysis if p value was less than 0.05. Backward stepwise logistic regression was performed. Survival curves of patients with and without VAP were obtained using the Kaplan–Meier method. The statistical analysis was performed SPSS Statistics 27 (IBM Corp, Armonk, New York, USA).
Results
During the study period, 451 COVID-19 patients were hospitalized in our intensive care unit; 121 (26.8%) of them were treated with noninvasive ventilation in our ICU and 330 (73.2%) patients underwent OTI, and of them, 133 patients (40.3%) were tracheostomized.

We excluded from the study 46 patients: 27 patients underwent invasive mechanical ventilation for less than 7 days; 10 patients were still admitted at the end of the study; 11 patients were transferred to other hospitals for competence, of which 6 patients transferred to an extracorporeal membrane oxygenation center (ECMO), 3 patients to a coronary care unit, and 2 patients to a surgical care unit (Fig. 1).

Baseline characteristics of COVID-19 patients with VAP
Demographics, comorbidities, and clinical features of ICU COVID-19 patients in MV with and without VAP are summarized in Table 1. The median age was 66 years (IQR, 58–73), and 71.5% were male. The median BMI was 27.7 kg/m² (IQR, 25–31), and median SOFA score and APACHE score at ICU admission were respectively 4.5 (IQR, 3–7) and 12 (IQR, 8–17). The most frequent comorbidities were arterial hypertension (54.9%), obesity (35.2%), cardiovascular disease (23.2%), diabetes (17.6%), and chronic lung disease (13.4%). The mean pre-ICU hospitalisation was 6 days (SD, ±8.0). The mean days on MV were 26.9 (SD, ±19.9), with a total accumulative time of 7638 days on mechanical ventilation. The mean ICU length of stay was 29.3 days (SD, ±19.8). The timeline distribution of VAPs from OTI is shown on Fig. 2. The median time to onset of VAP from intubation were 8 days (IQR, 5–13). Twenty-one patients (22%) had early-onset VAP (within the first 4 days of MV) and 73 of them (78%) had late-onset VAP (> 4 days MV). A comparison of patient demographics, clinical features, and etiological between early and late VAP are shown in Tables 1 and 2 of the supplemental material.

As shown in Table 1, renal placement therapy was used in 27 patients (9.5%), 109 patients (38.4%) underwent at least 10 h of pronation prior to the development of the VAP, 56 patients (19.5%) were treated with Tocilizumab or Sarilumab prior OTI, and 149 patients (51.9%) were treated with empirical antibiotic therapy prior OTI. At 30 days from ICU admission, 104 patients (36.6%) died and the overall ICU mortality rate was 42.2%.

Prevalence and incidence of VAP in ICU COVID-19 patients
During the study period, 103 episodes of VAP were diagnosed in 94 patients (9 patients had more than one episode), and the prevalence was 33% (94/284). The incidence rate of VAP was 13.48 (103 episodes/7638 days on MV) episodes per 1000 days in MV.

---

Fig. 1 Flowchart of study selection. COVID-19, coronavirus 2019; ICU, intensive care unit; IMV, invasive mechanical ventilation; NIV, non-invasive ventilation; VAP, ventilator-associated pneumonia
The etiology of the VAPs and its incidence are shown on Table 2. The incidence of Gram-negative bacteria was higher than that of Gram-positive bacteria, 12.4 and 1.04 VAPs per 1000 days on MV, respectively. The main etiological agents were *Pseudomonas aeruginosa* (41 episodes, 39.8% of all VAPs) of which 17 (41.4%) were carbapenem resistant, *Klebsiella spp.* (17 episodes, 16.5%) of which 10 (58.8%) were carbapenem resistant, *Staphylococcus aureus* (8 episodes, 7.7%) of which 4 (50%) were methicillin-resistant, *Acinetobacter baumannii* (8 episodes, 7.7%) of which all of them were carbapenem resistant, *Stenotrophomonas maltophilia* (8 episodes, 7.7%), *Escherichia coli* (6 episodes, 5.8%), *Serratia marcescens* (4 episodes, 4.8%), and *Proteus spp.* (4 episodes, 3.8%).

The accumulative total MV time in orotracheal tube was 4192 days and in tracheostomy were 3446 days. Patients during the mechanical ventilation in OTI had a higher overall incidence than those in tracheostomy.

### Table 1 Baseline demographic and clinical characteristics of patients at ICU admission

| Characteristics                              | Total 284 | VAP 94  | No VAP 190 | p value a |
|----------------------------------------------|-----------|---------|------------|-----------|
| Age, median (IQR)                            | 66 (58–73)| 66.5 (57–73)| 66 (58–74) | 0.806     |
| Male, n (%)                                  | 203 (71.5)| 60 (63.8)| 143 (75.3) | 0.245     |
| Female, n (%)                                | 81 (28.5)| 34 (36.2)| 47 (24.7)  | 0.245     |
| BMI, kg/m², median (IQR)                     | 27.7 (25–31)| 28.2 (25.4–32.4) | 27.6 (25–30.5) | 0.134     |
| SOFA score, median* (IQR)                    | 4.5 (3–7) | 6 (4–8) | 4 (3–7)    | **0.007** |
| APACHE II score, median* (IQR)               | 12 (8–17)| 13 (9–19)| 11.5 (7–16)| 0.068     |
| **Comorbidities, n (%)**                     |           |         |            |           |
| Arterial hypertension                        | 156 (54.9)| 51 (54.3)| 105 (55.2) | 0.873     |
| Cardiovascular diseases                      | 66 (23.2)| 28 (29.8)| 38 (20.0)  | 0.067     |
| Diabetes                                     | 50 (17.6)| 17 (18.1)| 33 (17.3)  | 0.897     |
| Obesity                                      | 100 (35.2)| 40 (42.5)| 60 (31.6)  | 0.069     |
| Chronic renal disease b                      | 13 (4.6)| 5 (5.3) | 8 (4.2)    | 0.675     |
| Chronic liver disease                        | 3 (1.0) | 3 (1.6) | 0 (0.0) | N.A       |
| Chronic lung disease                         | 38 (13.4)| 16 (17.0)| 22 (11.6)  | 0.206     |
| Previous neoplasm c                          | 14 (4.9)| 6 (6.4) | 8 (4.2)    | 0.719     |
| Chronic neurological disorders               | 29 (10.2)| 14 (14.9)| 15 (7.9)   | 0.067     |
| Autoimmune diseases                          | 29 (10.2)| 8 (8.5) | 21 (11.0)  | 0.507     |
| Other chronic diseases                       | 38 (13.4)| 12 (12.7)| 26 (13.7)  | 0.831     |
| **Clinical characteristics**                 |           |         |            |           |
| Previous surgery in last month               | 11 (3.9)| 4 (4.2) | 7 (3.7)    | 0.815     |
| Previous hospitalization last 6 months       | 21 (7.4)| 7 (7.4) | 14 (7.4)   | 0.981     |
| Pre-ICU hospitalization, days                | 6 (±8.0)| 4.7 (± 5.5)| 6.6 (± 9.0) | 0.072     |
| Total days on mechanical ventilation         | 26.9 (± 19.9)| 32.0 (± 18.6) | 24.3 (± 20.0) | **0.002** |
| ICU length of stay, days                     | 29.3 (± 19.8)| 33.4 (± 18.4)| 27.3 (± 20.2) | **0.015** |
| Renal placement therapy, no. (%)             | 27 (9.5)| 11 (11.7)| 16 (8.4)   | 0.835     |
| Barotrauma, no. (%)                          | 19 (6.7)| 4 (4.3) | 15 (7.9)   | 0.250     |
| Pronation d                                  | 109 (38.4)| 32 (34)| 77 (40.5) | 0.282     |
| Blood transfusion                            | 104 (36.2)| 45 (47.8)| 59 (31.0) | 0.006     |
| Tocilizumab/Sarilumab                        | 56 (19.5)| 26 (27.6)| 30 (15.8) | **0.018** |
| Pre-OTI antibiotic therapy e                  | 149 (51.9)| 55 (58.5)| 94 (49.5) | 0.152     |
| **Outcome**                                  |           |         |            |           |
| ICU discharged, patients, no. %              | 164 (57.8)| 50 (53.2)| 114 (60.0) | 0.276     |
| ICU mortality, patients, no. %               | 120 (42.2)| 44 (46.8)| 76 (40.0) | 0.276     |
| 30-day mortality, no. %                      | 104 (36.6)| 35 (37.2)| 69 (36.3) | 0.880     |
| 60-day mortality, no. %                      | 119 (41.9)| 43 (45.7)| 76 (40) | 0.358     |

IQR Interquartile range, ICU Intensive care unit, BMI Body mass index, SOFA score Sequential organ failure assessment and APACHE II score, acute physiologic, and chronic health evaluation at ICU admission. Obesity is defined as BMI > 30 kg/m². Stages 3–5 of CKD, chronic kidney disease. Includes solid neoplasia or hematological malignancy in the last 5 years. At least one cycle of 12 h. 30 days before orotracheal intubation.
16.46 (69/4192) and 9.86 (34/3446) episodes per 1000 days on MV, respectively.

*Pseudomonas aeruginosa* and *Klebsiella spp.* had an incidence respectively of 5.36 and 2.2 episodes per 1000 ventilator days. The timeline of the main bacterial agent, as *Acinetobacter baumanii*, *Pseudomonas aeruginosa*, and *Klebsiella spp.*, during the period of study are

![Timeline of onset of VAP from OTI. VAP, ventilator-associated pneumonia; OTI, orotracheal intubation](image)

**Table 2** Number of isolated microorganisms in ventilator-associated pneumonia episodes

| Microorganism                        | No. of VAPs | In OTI | In tracheostomy |
|--------------------------------------|-------------|--------|-----------------|
| **Gram-positive**                    |             |        |                 |
| Incidence (VAPs/1000 MV days)        | 8           | 7      | 1               |
| Methicillin-sensitive *Staphylococcus aureus* | 4           | 3      | 1               |
| Methicillin-resistant *Staphylococcus aureus* | 4           | 4      | 0               |
| **Gram-negative**                    | 95          | 62     | 33              |
| *Pseudomonas aeruginosa* (Carba-R)   | 41 (17)     | 24 (5) | 17 (12)         |
| *Klebsiella species* (Carba-R)       | 17 (3)      | 12 (0) | 5 (3)           |
| *K. pneumoniae* (Carba-R)            | 10 (2)      | 7 (0)  | 3 (2)           |
| *K. aerogenes* (Carba-R)             | 6 (1)       | 4 (0)  | 2 (1)           |
| *K. oxytoca*                         | 1           | 1      | 0               |
| *Stenotrophomonas maltophilia*       | 8           | 6      | 2               |
| *Acinetobacter spp.*                 | 8           | 7      | 1               |
| *Escherichia coli*                   | 6           | 4      | 2               |
| *Serratia marcescens*                | 5           | 3      | 2               |
| *Proteus spp.*                       | 4           | 0      | 4               |
| *Enterobacter cloacae*               | 3           | 3      | 0               |
| Others                               | 3           | 3      | 0               |
| **Total mechanical ventilation time, days** | 7638 days | 4192 days | 3446 days |
| Total VAP episodes                   | 103         | 69     | 34              |
| Incidence of VAP per 1000 MV days    | 13.48       | 16.46  | 9.86            |

VAP Ventilator-associated pneumonia, Carba-R Carbapenem-resistant, ICU Intensive care unit, OTI Otroracheal intubation, MV Mechanical ventilation
shown in Fig. 3a and b shows of Pseudomonas aeruginosa carbapenem susceptible vs resistant.

**Risk factors for VAP in ICU COVID-19 patients**

At univariate analysis, determinant factors significantly associated with VAP were SOFA score $\geq 4$ at ICU admission with a twice higher risk (OR 2.19, 95% CI 1.26–3.81, $p = 0.005$), female with a lower risk than male (OR 0.58, 95% CI 0.34–0.99, $p = 0.045$); blood transfusions prior to VAP with a twofold higher risk (OR 2.04, 95% CI 1.23–3.39, $p = 0.006$) (Table 3). Administration of Tocilizumab or Sarilumab was associated with a twofold higher risk (OR 2.03, 95% CI 1.12–3.70, $p = 0.018$) and ICU length of stay $> 28$ days with over twice higher risk (OR 2.29, 95% CI 1.38–3.79). Comorbidities, corticosteroid therapy, pronation, antibiotic therapy prior-OTI, and P/F ratio at ICU admission were determinant factors not significantly associated with the development of VAP. Moreover, VAP episodes did not significantly increase the mortality at 28 days from ICU admission and the overall ICU mortality rate (Fig. 4).

The multiple regression analysis shows that $\geq 4$ SOFA score (OR 2.11, 95% CI 1.20–3.71, $p = 0.009$), blood transfusion prior to VAP (OR 2.13, 95% CI 1.26–3.59, $p = 0.005$), treatment with Tocilizumab or Sarilumab (OR 2.08, 95% CI 1.12–3.84, $p = 0.02$), and $> 28$-day ICU LOS (OR 1.89, 95% CI 1.10–3.24) were all independent factors related to a twice higher risk of developing VAP.

**Discussion**

This study shows a 33% crude prevalence rate of VAP and an overall incidence density of 13.48 episodes per 1000 days of MV, higher than the incidence in non-COVID patients from the report of the Italian project GiViTi of 2019 (with an incidence of 9.8 events per 1000 ventilator days) [7] and of the European intensive care units (report of ECDC) in 2019 (9.5 episodes per 1000 ventilator days) [6]. However, the incidence of VAP is quite similar compared to studies including only ARDS patients as reported by Guerin et al. for PROSEVA trial in 2016 (between 11.8 and 15.4 VAP per 1000 ventilator days) [16].

VAP did not significantly increase the ICU mortality rate in our cohort, consistently with previous reports in COVID-19 [12], and non-COVID-19 patients, even with severe ARDS [7]. Improvement have occurred in the past few years in the management of ARDS patients in the ICU. Lung-protective ventilation strategies have been widely used in ARDS patients the past few decades and especially in the last 2 years of pandemic with COVID-19 ARDS patients [17, 18]. These strategies together with prompt antibiotic treatment may contribute to explaining this finding, as also some evidence indicates that cyclic stretch of pulmonary epithelial cells may represent an important pathogenic mechanism of VAP, promoting bacterial growth [19].

The sequential organ failure assessment (SOFA) score at ICU admission $\geq 4$ and ICU length of stay $> 28$ days were independently associated with higher risk of VAP, although ICU length of stay could be as much a cause as a consequence. SOFA score has been developed to assess the acute morbidity of critical illness and is widely used in predicting mortality and ICU length of stay in septic patients [20], as in some studies, it has been shown that it can also be a predictor for ventilator-associated pneumonia [21].

Ventilated patients in OTI had a 1.7-fold higher incidence of VAP than those in tracheostomy, 16.46 and 9.8
episodes per 1000 days on MV, respectively. Indeed, tracheostomy has many beneficial effects in MV patients, facilitating the weaning process, reducing the need for sedative and analgesics, reducing dead space and airway resistance, and finally, helping to maintain easier oral hygiene [22].

In our cohort, the most frequently isolated microorganisms were *Pseudomonas aeruginosa* (39.8%), *Klebsiella spp.* (16.5%), *Staphylococcus aureus* (7.7%), *Stenotrophomonas maltophilia* (7.7%), *Acinetobacter baumanii* (7.7%), and *Escherichia coli* (5.8%). Although some of the isolated microorganisms of our study are overlapping with those of the 2019 ECDC report, others such as *P. aeruginosa*, *Klebsiella spp.*, and *A. baumanii* have higher incidence. This is likely to be due to the SARS-CoV-2-related upper respiratory tract microbiome dysbiosis reported in some studies, correlated to a profoundly altered microbiome profile through different mechanisms, as known for other respiratory viruses, including alteration of the respiratory epithelium, promotion of adhesion of respiratory pathogens, and increase of local inflammation [23, 24].

Carbapenem resistance resulted in all *Acinetobacter spp.* and in 41.4% of *P. aeruginosa* isolates with a 56% and 60% increase over the ECDC report in 2019 (63.9% and 25.9%, respectively). Instead, carbapenem resistance in *Klebsiella spp.* isolates was 17.6%, which is slightly higher to that reported by ECDC in 2019 (15.2%). Half of *S. aureus* were methicillin-resistant (MRSA) with a 113% increase over ECDC report in 2019 (23.5%). Widespread and inappropriate prescription of broad-spectrum antibiotics as prophylaxis for COVID-19 (usually beta-lactams, macrolides, and fluoroquinolones) has been observed during the pandemic, as discussed in the 32nd European

### Table 3

Unadjusted and adjusted risk factors for developing at least one VAP in ICU COVID-19 patients

| Variable | Total ICU patients | VAP group | Univariate OR (95% CI) | Multivariate aOR (95% CI) |
|----------|--------------------|-----------|------------------------|--------------------------|
|          | 284                | 94 (33)   |                        |                          |
| Age > 70 years old | 111 | 37 (33.3) | 1.02 (0.61–1.69) | 0.946 |
| Female (vs male), n (%) | 203 | 60 (29.6) | 0.58 (0.34–0.99) | **0.045** 0.69 (0.39–1.22) | 0.205 |
| SOFA score ≥ 4 | 182 | 71 (39) | 2.19 (1.26–3.81) | **0.005** 2.11 (1.20–3.71) | **0.009** |
| APACHE II score ≥ 10 | 182 | 67 (36.8) | 1.62 (0.95–2.76) | 0.076 1.05 (0.55–2.00) | 0.883 |
| Comorbidities, n (%) |          |                        |                          |                          |
| Arterial hypertension | 156 | 51 (32.7) | 0.96 (0.58–1.58) | 0.872 |
| Cardiovascular diseases | 66 | 28 (42.4) | 1.69 (0.96–2.99) | 0.066 1.56 (0.85–2.83) | 0.148 |
| Diabetes | 50 | 17 (34) | 1.05 (0.55–2.00) | 0.881 |
| Obesity a | 100 | 40 (40) | 1.60 (0.96–2.67) | 0.068 1.55 (0.91–2.65) | 0.106 |
| Chronic lung disease | 38 | 16 (42.1) | 1.56 (0.78–3.15) | 0.205 |
| Chronic renal disease b | 13 | 5 (38.5) | 1.27 (0.40–4.02) | 0.674 |
| Renal placement therapy | 27 | 11 (40.7) | 1.44 (0.64–3.24) | 0.375 |
| Previous neoplasms c | 15 | 6 (40) | 1.37 (0.47–3.97) | 0.559 |
| Chronic neurological disorders | 29 | 14 (48.3) | 2.04 (0.94–4.43) | 0.067 |
| Autoimmune diseases | 29 | 8 (27.6) | 0.75 (0.32–1.76) | 0.506 |
| Other chronic diseases | 38 | 12 (31.6) | 0.92 (0.44–1.92) | 0.830 |
| Clinical characteristics |          |                        |                          |                          |
| Corticosteroid therapy | 201 | 69 (34.3) | 1.21 (0.69–2.10) | 0.493 |
| Pronation d | 109 | 32 (29.4) | 0.76 (0.45–1.27) | 0.290 |
| Barotrauma | 19 | 4 (21.1) | 0.52 (0.17–1.60) | 0.248 |
| Blood transfusion | 104 | 45 (43.3) | 2.04 (1.23–3.39) | **0.006** 2.13 (1.26–3.59) | **0.005** |
| Tocilizumab/Sarilumab | 56 | 26 (46.4) | 2.03 (1.12–3.70) | **0.018** 2.08 (1.12–3.84) | **0.020** |
| Pre-OTI antibiotic therapy | 149 | 55 (36.9) | 1.44 (0.87–2.37) | 0.151 |
| PaO2/FiO2 ≤ 100 mmHg | 48 | 16 (33.3) | 1.01 (0.52–1.95) | 0.970 |
| ICU length of stay > 28 days | 113 | 50 (44.2) | 2.29 (1.38–3.79) | **0.001** 1.89 (1.10–3.24) | **0.020** |
| 30-day ICU mortality | 104 | 35 (33.7) | 1.04 (0.62–1.73) | 0.880 |
| Overall ICU mortality | 120 | 44 (36.7) | 1.32 (0.80–2.17) | 0.274 |

IQR Interquartile range, ICU Intensive care unit, BMI Body mass index, SOFA score Sequential organ failure assessment and APACHE II score, Acute physiologic and chronic health evaluation at ICU admission. aObesity is defined as BMI > 30 kg/m²; bStages 3–5 of CKD, chronic kidney disease; cIncludes solid neoplasia or hematological malignancy in the last 5 years; dAt least one cycle of 12 h
Congress of Clinical Microbiology & Infectious Diseases (ECCMID), presented on April 23–26, 2022 [25], showing high rates of antimicrobial resistance in COVID-19 patients. As expected, also in our study, a high percentage of our patients (52.4%) used broad-spectrum antibiotics prior to ICU admission and often started before admission to hospital. The overuse of empirical antibiotics before intubation could have led to an unfavorable development of multidrug resistant bacteria, as a high proportion of carbapenem resistance and MRSA microorganisms.

Late-onset VAP were more likely to be caused by multidrug-resistant (MDR) pathogens (Table 2, Supplemental Material).

Demographics (age, sex), comorbidities, renal placement therapy, \( \text{PaO}_2/\text{FiO}_2 \) at ICU admission, and empirical antibiotic therapy prior OTI were not associated with a higher risk of VAP, consistently with the data reported by Blonz et al. [11]. Barotrauma, as pneumothorax or pneumomediastinum, in our ICU COVID-19 patients had a relatively low incidence [26], and it was not associated with a higher risk of VAP. Moreover, blood transfusion during the ICU stay had an independent higher risk of developing VAPs, as reported in a multicenter study including 284 intensive care units in the USA in non-COVID-19 population, by Shorr et al. [27]. An experimental hypothesis is that blood transfusion promotes the release of cytokines, which enhances various cytokine cascades producing pulmonary inflammation, as well as bronchoalveolar activation of coagulation [28].

The patient’s body position is an important aspect in ICU. A semi-recumbent position (i.e., elevation of the head of bed to 30–45°) has been widely used in our ICU as a strategy for patients undergoing MV as a recommendable measure in several clinical practice guidelines for preventing VAP [29]. This position can help reduce gastroesophageal reflux and avoid the entry of gastric contents and contaminated oropharyngeal secretions into the lower airway [29]. An early application of prone position seems to have a survival benefit in patients with moderate-severe ARDS, promoting the distribution of the gas–tissue ratios along the dependent–nondependent axis and a more homogeneous distribution of lung stress and strain [30]. Indeed, during the pandemic prone position has been a common strategy in COVID-19 patients with refractory hypoxemia [31]. Although the prone position appears not to be associated with a higher risk of VAP, as reported as well by Ayzac et al. in the PROSEVA trial in 2016 and in a recent review by Pozuelo-Carrascosa et al. in 2022, in intubated patients with severe ARDS, and our results are consistent with them [16, 29].

Interleukin-6 acts as a fundamental cytokine in organizing T cell responses to infections and, eventually, may protect against superinfection. Tocilizumab or Sarilumab are anti IL-6 receptor monoclonal antibodies, approved for the treatment of multiple inflammatory diseases, and have been considered for off-label use in the treatment of COVID-19 [32, 33]. We found that Tocilizumab/Sarilumab had a significant association with a twofold higher
risk of VAP at both univariate and multivariate analysis, consistently with data reported by Martinez et al. [34].

This study has a major limitation. This is an observational study conducted in a single center with a 6-month observation period on a limited population of approximately 300 MV COVID-19 patients; however, our prevalence and incidence rate are in line with literature data, and it represent a first step to formulate hypothesis to design of larger clinical studies.

Conclusions
Our study shows an incidence of VAP in COVID-19 patients higher than that reported in non-COVID-19 patients [6], but in line with the data reported in ARDS patients in pre-COVID era [16]. Patients with tracheostomy had a reduced incidence of VAPs, and a correct timing of tracheostomy in MV patients is a key strategy to reduce VAP. Conversely, interleukin-6 inhibitors and blood transfusion in our COVID-19 patients have been all recognized as independent risk factors for developing VAP. Prone position did not increase this risk.

We reported a high incidence of carbapenem resistance Pseudomonas aeruginosa and MRSA, likely related to an increased use of empirical antibiotics. Since management practices for COVID-19 patients in the ICU are constantly evolving, the widespread use of empirical antibiotics in these patients and optimal infection control measures by implementation of antimicrobial stewardship programs should be all taken into consideration, to avoid the development of multidrug-resistant bacteria.

Finally, VAP did not increase the ICU case mortality rate.

Abbreviations
COVID-19: Coronavirus 2019; ICU: Intensive care unit; MV: Invasive mechanical ventilation; NIV: Non-invasive ventilation; VAP: Ventilator-associated pneumonia; NIV: Non-invasive ventilation; VAP: Ventilator-associated pneumonia; NIV; Non-invasive ventilation; VAP: Ventilator-associated pneumonia; COVID-19: Coronavirus 2019; ICU: Intensive care unit; MV: Invasive mechanical ventilation.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s44158-022-00065-4.

Additional file 1: Table 1. Comparison of demographic and clinical characteristics of patients by early and late VAP. Table 2. Number of isolated microorganisms in ventilator-associated pneumonia episodes by early and late VAP.

Acknowledgements
We gratefully acknowledge the collaborating members of the ICU COVID-19 study group: Grisaro Adele, Farina Anna, Merino Cabas Ricardo, Jose, Micarelli Sibiana, Petroselli Valeria, Ragosta Giuseppina, and Zito Sara.

Ethical approval
Ethical approval: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Ethics Committee of IRCCS L. Spallanzani. Data acquisition and analysis were performed in compliance with protocols approved by the Ethical Committee of the National Institute for Infectious Diseases IRCCS Lazzaro Spallanzani, Rome, Italy (ethical approval number 164, 26 June 2020).

Authors’ contributions
Conceptualization, N.T., A.C., and L.M.; methodology, N.T., L.M., and A.C.; validation, L.M., A.C., and E.N.; formal analysis, N.T. and L.M.; investigation, all authors; resources, all authors; data curation, all authors; writing—original draft preparation, N.T. and L.M.; writing—review and editing, N.T., L.M., E.N., and A.C.; visualization, L.M., E.G., F.P., C.N., G.G., P.C., M.A.C., S.I., R.D.L., D.B., D.R., and A.A.; supervision, L.M., A.C., and E.N. The authors have read and agreed to the final version of the manuscript.

Funding
This work was supported by the INMI “Lazzaro Spallanzani” Ricerca Finalizzata COVID-2020–12371675 and Ricerca Corrente on emerging infections, both funded by the Italian Ministry of Health.

Availability of data and materials
The data presented in this study are available on request from the corresponding author. The data are not publicly available because of patient privacy and data protection regulations.

Declarations
Consent for publication
Informed consent was obtained from all subjects involved in the study.

Competing interests
The authors declare that they have no competing interests.

Author details
1 National Institute for Infectious Diseases IRCCS Lazzaro Spallanzani, Rome, Italy. 2 UOC Resuscitation, Intensive and Sub-Intensive Care, National Institute for Infectious Diseases IRCCS Lazzaro Spallanzani, 00149 Rome, Italy. 3 Clinical and Research Department of Infectious Diseases, National Institute for Infectious Diseases IRCCS Lazzaro Spallanzani, 00149 Rome, Italy. 4 Health Direction, National Institute for Infectious Diseases IRCCS Lazzaro Spallanzani, 00149 Rome, Italy. 5 Scientific Direction, National Institute for Infectious Diseases IRCCS Lazzaro Spallanzani, 00149 Rome, Italy.

Received: 1 July 2022 Accepted: 8 August 2022 Published online: 19 August 2022

References
1. WHO Coronavirus Disease (COVID-19) Dashboard | WHO coronavirus disease (COVID-19) Dashboard. Available online: https://covid19.who.int/ (Accessed on 27 May 2022).
2. Privitera D, Angaroni L, Capsoni N, Forni E, Pierotti F, Vinciotti F, Bellone A (2020) Flowchart for non-invasive ventilation support in COVID-19 patients from a Northern Italy Emergency Department. Intern Emerg Med 15:767–771. https://doi.org/10.1007/s11739-020-02370-8
3. Mehta C, Mehta Y (2017) Percutaneous tracheostomy. Ann Card Anaesth 20:159–525. https://doi.org/10.4103/0971-9784.197793
4. Koulenti D, Tsigou E, Rello J (2017) Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study. Eur J Clin Microbiol Infect Dis 36:1999–2006. https://doi.org/10.1007/s10096-016-2703-2
5. Torres A, Niederman MS, Chatrre J, Ewig S, Fernandez-Vandelllos P, Hanberger H, Koller M, Li Bassi G, Luna CM, Martin-Loeches I et al (2017) International ERS/ESICM/ESCMM/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. Eur Respir J 50:1700582. https://doi.org/10.1183/13993003.00582-2017
6. European Centre for Disease Prevention and Control. Healthcare-associated infections acquired in intensive care units. In: ECDC. Annual
